Report Summary
Eternity Insights can provide a deep dive research report highlighting the market and competitive in-telligence across the key segments of the market. The report also considers the impact of COVID-19 on the global Hematologic Malignancies market. The report considers 2018-2020 historic period, 2021 as base year, and 2022-2028 as forecast period. The report includes quantitative analysis of the market supported by the mar-ket drivers, challenges, and trends to accurately map the market scenario and competition.
Hematologic Malignancies market report is based on robust research methodology designed using blend of research ap-proaches developed using secondary/desk research and validated through the primary research and expert insights. Eternity Insights also uses paid data bases such as FACIVA, Hoovers, and other bench-marking and forecasting tools to provide accurate statistical analysis of supply and demand trends.
To learn more about this report
Key Research Highlights: Market Drivers
The Hematologic Malignancies market is estimated to expand at a considerable growth rate during the forecast period ow-ing to increasing prevalence of venous diseases and increasing new product approvals to cater this demand. Rise in the awareness about the diseases, increasing importance of early diagnosis, and growing spending on chronic diseases are poised to boost the market growth. Moreover, the key players in the market are investing in research and development of technologically advanced products leading to increased utilization of the Hematologic Malignancies products across developed and developing countries of the world.
Key Research Highlights: Market Restrains
Limited awareness about the diseases, high cost of products, low economical condition, and lack of favorable insurance systems restricts the adoption of Hematologic Malignancies products across developing regions of the globe. However, launch of new products with low cost and increasing efforts for market penetration in these regions can offer lucrative growth opportunities for the players in the Hematologic Malignancies market.
To learn more about this report
Key Research Highlights: Trends
Increasing research and development spending on Hematologic Malignancies development has been the leading industry trend of Hematologic Malignancies market
The leading players in the market are focused on developing products which are cost effective and high quality to tap the huge unaddressed opportunities in the developing regions. This can be wit-nessed from the increasing spending on research and development and growing number of new product approvals.
Global Hematologic Malignancies Market Size, 2018-2028 (USD MILLION)
To learn more about this report
Market Segmentation
| Report Attributes |
Details |
| The market size value in 2021 |
USD XX.XX Million |
| CAGR (2021 - 2028) |
XX.XX % |
| The Revenue forecast in 2028 |
USD XX.XX Million |
| Base year for estimation |
2021 |
| Historical data |
2018-2019 |
| Forecast period |
2022-2028 |
| Quantitative units |
- Revenue in USD Million
- CAGR from 2021 to 2028
|
| Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered |
By Type Outlook, Application Outlook, Regional Outlook |
| By Type Outlook |
Leukemia, Lymphoma, Multiple Myeloma, Others |
| By Application Outlook |
Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation, Others |
| Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Country scope |
U.S., Canada, U.K., Germany, France, BENELUX, China, India, Japan, South Korea, Brazil, Saudi Arabia, UAE, Turkey |
| Key companies profiled |
Pfizer, Inc., F. Hoffmann-LA Roche ltd, Sanofi-Aventis, Bristol-Myers Squibb Company, AbbVie, Inc., Novartis AG, GlaxoSmithKline PLC, Celgene Corporation, Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company limited |
| Customization Available |
Yes, the report can be tailored to meet your specific requirements. |
Key Market Players
- Pfizer
- Inc.
- F. Hoffmann-LA Roche ltd
- Sanofi-Aventis
- Bristol-Myers Squibb Company
- AbbVie
- Inc.
- Novartis AG
- GlaxoSmithKline PLC
- Celgene Corporation
- Johnson & Johnson Services
- Inc.
- Takeda Pharmaceutical Company limited
HEMATOLOGIC MALIGNANCIES Market, By Type
- Leukemia
- Lymphoma
- Multiple Myeloma
- Others
HEMATOLOGIC MALIGNANCIESMarket, By Application
- Chemotherapy
- Radiotherapy
- Immunotherapy
- Stem Cell Transplantation
- Others
Key Benefits To The Stake Holders
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) and volume (Tons) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Table Of Contents
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Hematologic Malignancies Market Size Growth Rate by Type (2013-2025)
1.4.2 Leukemia
1.4.3 Lymphoma
1.4.4 Multiple Myeloma
1.4.5 Others
1.5 Market by Application
1.5.1 Global Hematologic Malignancies Market Share by Application (2013-2025)
1.5.2 Chemotherapy
1.5.3 Radiotherapy
1.5.4 Immunotherapy
1.5.5 Stem Cell Transplantation
1.5.6 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Hematologic Malignancies Market Size
2.2 Hematologic Malignancies Growth Trends by Regions
2.2.1 Hematologic Malignancies Market Size by Regions (2013-2025)
2.2.2 Hematologic Malignancies Market Share by Regions (2013-2018)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities
3 Market Share by Key Players
3.1 Hematologic Malignancies Market Size by Manufacturers
3.1.1 Global Hematologic Malignancies Revenue by Manufacturers (2013-2018)
3.1.2 Global Hematologic Malignancies Revenue Market Share by Manufacturers (2013-2018)
3.1.3 Global Hematologic Malignancies Market Concentration Ratio (CR5 and HHI)
3.2 Hematologic Malignancies Key Players Head office and Area Served
3.3 Key Players Hematologic Malignancies Product/Solution/Service
3.4 Date of Enter into Hematologic Malignancies Market
3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type and Application
4.1 Global Hematologic Malignancies Market Size by Type (2013-2018)
4.2 Global Hematologic Malignancies Market Size by Application (2013-2018)
5 United States
5.1 United States Hematologic Malignancies Market Size (2013-2018)
5.2 Hematologic Malignancies Key Players in United States
5.3 United States Hematologic Malignancies Market Size by Type
5.4 United States Hematologic Malignancies Market Size by Application
6 Europe
6.1 Europe Hematologic Malignancies Market Size (2013-2018)
6.2 Hematologic Malignancies Key Players in Europe
6.3 Europe Hematologic Malignancies Market Size by Type
6.4 Europe Hematologic Malignancies Market Size by Application
7 China
7.1 China Hematologic Malignancies Market Size (2013-2018)
7.2 Hematologic Malignancies Key Players in China
7.3 China Hematologic Malignancies Market Size by Type
7.4 China Hematologic Malignancies Market Size by Application
8 Japan
8.1 Japan Hematologic Malignancies Market Size (2013-2018)
8.2 Hematologic Malignancies Key Players in Japan
8.3 Japan Hematologic Malignancies Market Size by Type
8.4 Japan Hematologic Malignancies Market Size by Application
9 Southeast Asia
9.1 Southeast Asia Hematologic Malignancies Market Size (2013-2018)
9.2 Hematologic Malignancies Key Players in Southeast Asia
9.3 Southeast Asia Hematologic Malignancies Market Size by Type
9.4 Southeast Asia Hematologic Malignancies Market Size by Application
10 India
10.1 India Hematologic Malignancies Market Size (2013-2018)
10.2 Hematologic Malignancies Key Players in India
10.3 India Hematologic Malignancies Market Size by Type
10.4 India Hematologic Malignancies Market Size by Application
11 Central & South America
11.1 Central & South America Hematologic Malignancies Market Size (2013-2018)
11.2 Hematologic Malignancies Key Players in Central & South America
11.3 Central & South America Hematologic Malignancies Market Size by Type
11.4 Central & South America Hematologic Malignancies Market Size by Application
12 International Players Profiles
12.1 Pfizer, Inc.
12.1.1 Pfizer, Inc. Company Details
12.1.2 Company Description and Business Overview
12.1.3 Hematologic Malignancies Introduction
12.1.4 Pfizer, Inc. Revenue in Hematologic Malignancies Business (2013-2018)
12.1.5 Pfizer, Inc. Recent Development
12.2 F. Hoffmann-LA Roche ltd
12.2.1 F. Hoffmann-LA Roche ltd Company Details
12.2.2 Company Description and Business Overview
12.2.3 Hematologic Malignancies Introduction
12.2.4 F. Hoffmann-LA Roche ltd Revenue in Hematologic Malignancies Business (2013-2018)
12.2.5 F. Hoffmann-LA Roche ltd Recent Development
12.3 Sanofi-Aventis
12.3.1 Sanofi-Aventis Company Details
12.3.2 Company Description and Business Overview
12.3.3 Hematologic Malignancies Introduction
12.3.4 Sanofi-Aventis Revenue in Hematologic Malignancies Business (2013-2018)
12.3.5 Sanofi-Aventis Recent Development
12.4 Bristol-Myers Squibb Company
12.4.1 Bristol-Myers Squibb Company Company Details
12.4.2 Company Description and Business Overview
12.4.3 Hematologic Malignancies Introduction
12.4.4 Bristol-Myers Squibb Company Revenue in Hematologic Malignancies Business (2013-2018)
12.4.5 Bristol-Myers Squibb Company Recent Development
12.5 AbbVie, Inc.
12.5.1 AbbVie, Inc. Company Details
12.5.2 Company Description and Business Overview
12.5.3 Hematologic Malignancies Introduction
12.5.4 AbbVie, Inc. Revenue in Hematologic Malignancies Business (2013-2018)
12.5.5 AbbVie, Inc. Recent Development
12.6 Novartis AG
12.6.1 Novartis AG Company Details
12.6.2 Company Description and Business Overview
12.6.3 Hematologic Malignancies Introduction
12.6.4 Novartis AG Revenue in Hematologic Malignancies Business (2013-2018)
12.6.5 Novartis AG Recent Development
12.7 GlaxoSmithKline PLC
12.7.1 GlaxoSmithKline PLC Company Details
12.7.2 Company Description and Business Overview
12.7.3 Hematologic Malignancies Introduction
12.7.4 GlaxoSmithKline PLC Revenue in Hematologic Malignancies Business (2013-2018)
12.7.5 GlaxoSmithKline PLC Recent Development
12.8 Celgene Corporation
12.8.1 Celgene Corporation Company Details
12.8.2 Company Description and Business Overview
12.8.3 Hematologic Malignancies Introduction
12.8.4 Celgene Corporation Revenue in Hematologic Malignancies Business (2013-2018)
12.8.5 Celgene Corporation Recent Development
12.9 Johnson & Johnson Services, Inc.
12.9.1 Johnson & Johnson Services, Inc. Company Details
12.9.2 Company Description and Business Overview
12.9.3 Hematologic Malignancies Introduction
12.9.4 Johnson & Johnson Services, Inc. Revenue in Hematologic Malignancies Business (2013-2018)
12.9.5 Johnson & Johnson Services, Inc. Recent Development
12.10 Takeda Pharmaceutical Company limited
12.10.1 Takeda Pharmaceutical Company limited Company Details
12.10.2 Company Description and Business Overview
12.10.3 Hematologic Malignancies Introduction
12.10.4 Takeda Pharmaceutical Company limited Revenue in Hematologic Malignancies Business (2013-2018)
12.10.5 Takeda Pharmaceutical Company limited Recent Development
13 Market Forecast 2018-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2018-2025)
13.10 Market Size Forecast by Application (2018-2025)
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details
